BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Rote-Hand-Brief on Refludan® PDF, 347KB, File is accessible Date: 21. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: lepirudin

Dear Doctor Letter (Rote-Hand-Brief) on Advagraf® 0.5 mg hard capsules (tacrolimus): Risk of increased blood levels of tacrolimus due to use of particular batches PDF, 299KB, File is accessible Date: 21. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tacrolimus

The pharmaceutical manufacturer issues information on the fact that there is a risk of higher levels of tacrolimus in the blood of patients taking Advagraf® 0.5 mg hard capsules due to quality defects detected in particular batches. The …

Dear Doctor Letter (Rote-Hand-Brief) on Refludan® (lepirudin): Permanent discontinuation of the distribution of Refludan® PDF, 347KB, File is accessible Date: 21. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: lepirudin

The pharmaceutical manufacturer issues information on the planned permanent discontinuation of the distribution of Refludan® as of 1 April 2012 as well as on switching patients currently taking Refludan® to treatment alternatives in due time.

Rote-Hand-Brief on Revlimid® PDF, 479KB, File is accessible Date: 20. October 2011 Topics: Pharmakovigilanz Type: Download

Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Risk of second primary malignancies PDF, 479KB, File is accessible Date: 20. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: lenalidomide

Important information on the risk of second primary malignancies in patients treated with Revlimid® (lenalidomide). Results of the benefit-risk review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines …

Information Letter on Methergin® PDF, 57KB, File is accessible Date: 14. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: methylergometrine maleate

Information letter regarding Methergin® (methylergometrine maleate): Withdrawal of Methergin® oral solution from the market, safety information for the use of Methergin® solution for injection PDF, 57KB, File is accessible Date: 14. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: methylergometrine maleate

The pharmaceutical manufacturer issues information on the withdrawal of Methergin® oral solution from the market due to case reports of adverse drug reactions in connection with medication errors/misuse in neonates. In addition, safety …

Rote-Hand-Brief on Revatio® PDF, 215KB, File is accessible Date: 06. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: sildenafil citrate

Dear Doctor Letter (Rote-Hand-Brief) on Revatio® (sildenafil citrate): Increased risk of mortality in paediatric patients with pulmonary arterial hypertension (PAH) PDF, 215KB, File is accessible Date: 06. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: sildenafil citrate

Important new safety information on the increased risk of mortality in paediatric patients with pulmonary arterial hypertension (PAH) in connection with the use of higher than recommended doses of Revatio® (sildenafil citrate).

Rote-Hand-Brief on Multaq® PDF, 439KB, File is accessible Date: 30. September 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dronedarone